Overlay Shares Short Term Bond ETF (ARCA: OVT)

Overlay Shares Short Term Bond ETF (ARCA:OVT), Trade Ideas

Overlay Shares Short Term Bond ETF

OCULUS VISIONTECH INC by Oculus Visiontech, Inc.

Oculus VisionTech Inc

<p>Thursday,&nbsp;<strong>Benitec Biopharma Inc</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) released interim clinical data from the 90-day timepoint following the administration of BB-301 to the study&#8217;s first subject (Subject 1) treated in the BB-301 Phase 1b/2a study in&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38310794/benitec-biopharma-reports-positive-interim-clinical-trial-data-for-first-opmd-subject-treated-with" rel="noreferrer noopener">Oculopharyngeal Muscular Dystrophy</a>&nbsp;(OPMD).</p>
<p>&#8220;To date, no clinical studies have systematically demonstrated a clinical improvement in OPMD patients across both objective and subjective measures of swallowing. We are, therefore, pleased to report positive interim clinical data from multiple radiographic measures as well as subject-reported outcome measures from the first subject treated with BB-301,&#8221; said Jerel Banks, Executive Chairman and Chief Executive Officer of Benitec.&nbsp;</p>
<p>During the OPMD Natural History Study, which represents the pre-dose observational period for each subject, Subject 1 experienced progressive worsening of dysphagia (difficulty swallowing) as demonstrated by the results of the videofluoroscopic swallowing studies (VFSS), the cold water timed drinking test.</p>
<p>At the 90-day timepoint following the administration of BB-301, Subject 1 demonstrated improvements in key videofluoroscopic assessments.</p>
<p>The results of many assessments completed at the 90-day timepoint demonstrated improvements over the initial measurements assessed at the subject&#8217;s first visit for the natural history observational study, which occurred more than 12 months before the 90-day assessment.</p>
<p>The most significant VFSS improvements at Day 90 were observed for swallowing tasks centered on evaluating pharyngeal constrictor muscle function and swallowing efficiency in consuming thin liquids, solid foods, and thick, non-solid foods.&nbsp;</p>
<p>So far, no severe side effects have been noted in the safety profile of BB-301. Two subjects experienced temporary Grade 2 (mild) Gastroesophageal Reflux Disease (GERD), which was treated with standard prescription medication.</p>
<p>OPMD is a rare progressive muscle-wasting disease caused by a poly(A)-binding protein nuclear 1 gene mutation. The disease is characterized by swallowing difficulties (dysphagia), limb weakness, and eyelid drooping (ptosis). Dysphagia worsens over time.</p>
<p>Concurrently, Benitec Biopharma announced a $40 million private investment in public equity (PIPE) financing from the sale of 5.7 million shares at $4.80/share and in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 2.58 million shares at a price per pre-funded warrant of $4.7999, to<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38310080/benitec-biopharma-announces-oversubscribed-private-placement-financing-of-40-0-million" rel="noreferrer noopener">&nbsp;certain institutional accredited investors.</a></p>
<p><strong>Price Action:</strong> BNTC shares are up 24% at $5.95 on the last check Thursday.</p>
<p><em>Illustration of Phrama lab worker created with MidJourney.</em></p>


Biotech

Equities

News

Health Care

Movers

Trading Ideas

General

BNTC

Why Is Gene Therapy Developer Benitec Biopharma Stock Trading Higher On Thursday?

<p>Wedbush  analyst Scott Devitt   reiterates Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Outperform and maintains $3850 price target.</p>


Price Target

Reiteration

Analyst Ratings

BKNG

Wedbush Reiterates Outperform on Booking Holdings, Maintains $3850 Price Target

WIIM

$BTC

Bitcoin is trading higher amid volatility ahead of the upcoming halving.

<p>Dover (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Dover, revealing an average target of $180.56, a high estimate of $205.00, and a low estimate of $153.00. Surpassing the previous average price target of $167.62, the current average has increased by 7.72%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713459758_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Dover. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bryan Blair</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$187.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$205.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$180.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$185.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$185.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Walt Liptak</td>
<td>Seaport Global</td>
<td>Announces</td>
<td>Buy</td>
<td>$190.00</td>
<td>-</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$163.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$153.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>Bryan Blair</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$177.00</td>
<td>$175.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Dover. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dover compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Dover's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Dover's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DOV/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Dover analyst ratings.</strong></a></p>
<h2>About Dover</h2>
<p>Dover is a diversified manufacturer and solutions provider delivering equipment and components, consumable supplies, aftermarket parts, software digital solutions, and support services. It operates through five segments: engineered systems, clean energy, and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.</p>
<h3>Dover: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Dover's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately <strong>-1.56%</strong> in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Dover's net margin excels beyond industry benchmarks, reaching <strong>14.07%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>5.96%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Dover's ROA excels beyond industry benchmarks, reaching <strong>2.68%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Dover's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.72</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What 9 Analyst Ratings Have To Say About Dover

<p>During the last three months, 8 analysts shared their evaluations of Fiverr Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVRR#NYSE">FVRR</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Fiverr Intl and provided 12-month price targets. The average target is $31.75, accompanied by a high estimate of $40.00 and a low estimate of $25.00. A 5.7% drop is evident in the current average compared to the previous average price target of $33.67. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713459723_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Fiverr Intl among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marvin Fong</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$32.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$26.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$33.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Matt Farrell</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$40.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Fiverr Intl. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Fiverr Intl compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Fiverr Intl's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Fiverr Intl's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FVRR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Fiverr Intl analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Fiverr Intl: A Closer Look</h2>
<p>Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Wiring and Translation, and Video and Animation among others.</p>
<h3>Breaking Down Fiverr Intl's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Fiverr Intl's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately <strong>10.07%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Fiverr Intl's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>5.14%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Fiverr Intl's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>1.39%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Fiverr Intl's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.46%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Fiverr Intl's debt-to-equity ratio surpasses industry norms, standing at <strong>1.3</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FVRR

Demystifying Fiverr Intl: Insights From 8 Analyst Reviews

<p>Ninety-six percent, or 480 out of the 500 companies comprising the S&amp;P 500 index, are trading at lower market values compared to Wall Street analysts&#8217; price targets, signaling abundant potential <a href="https://www.benzinga.com/markets">profit opportunities for investors.</a></p>
<p>Thus far, April has marked the bleakest month for the U.S. stock market since September 2023, with the S&amp;P 500 index, tracked by the <strong>SPDR S&amp;P 500 ETF Trust</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), falling by 3.7%.</p>
<p>Across all 11 sectors constituting the index, only the <strong>Energy Select Sector SPDR Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) has managed to evade losses. The <strong>Real Estate Select Sector SPDR Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) emerged as the month&#8217;s weakest performer, experiencing a 10% downturn.</p>
<p>Higher-than-expected inflation figures have placed downward pressure on stocks, leading to reduced expectations for Federal Reserve rate cuts. As of April 18, investors expect fewer than two rate cuts, down from over three anticipated at the beginning of the month.</p>
<p>Simultaneously, mounting geopolitical risks stemming from the ongoing Middle East crisis have amplified market uncertainties.</p>
<p>However, this phase of increased volatility has subdued the once prevalent bullish sentiment that persisted until the end of March, uncovering attractive opportunities for investors who favor buying the dips of undervalued stocks.</p>
<p>Presented herein are the top 5 contrarian stocks within the S&amp;P 500 index exhibiting the most pronounced relative gap between current market prices and median price targets.</p>
<h3 class="wp-block-heading">5. <strong>Carnival Corp</strong>oration</h3>
<p><strong>Carnival Corp.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) has experienced a noticeable downturn, dropping by 11.54% this month and 22.03% year-to-date. </p>
<p>Analysts, however, have maintained consistency in their price forecasts. At the beginning of the year, the median target was $20.78, which has since held steady at $22. </p>
<p>This suggests a substantial 52.20% potential upside from the current trading price of $14.46 per share.</p>
<h3 class="wp-block-heading">4. Bio-Rad Laboratories, Inc.</h3>
<p><strong>Bio-Rad Laboratories, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) has witnessed an 18.81% decline in price this month and a 13.03% decrease year-to-date. </p>
<p>Despite market fluctuations, the median price target has remained unchanged at $436.70 since the beginning of 2024.</p>
<p>Presently trading at $280.81 per share, this implies that analysts see a potential upside of 55.51% if the stock price converges with the target.</p>
<h3 class="wp-block-heading">3. Warner Bros. Discovery, Inc.</h3>
<p><strong>Warner Bros. Discovery, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) has declined 5.27% this month and by a substantial 27.33% year-to-date. </p>
<p>Analysts have downwardly adjusted their price targets for WBD shares, reducing the median level from $16.64 at the beginning of the year to $13 presently. </p>
<p>Despite these downward revisions, the current share price of $8.27 still provides some margin of safety to investors, indicating a potential 57.19% upside if it converges with analysts&#8217; targets.</p>
<h3 class="wp-block-heading">2. Caesars Entertainment Inc. </h3>
<p><strong>Caesars Entertainment Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NYSE">CZR</a>) has declined by 11.25% month-to-date and a more substantial 17.19% year-to-date. </p>
<p>However, despite these negative trends, analysts have made minimal adjustments to their price targets for the casino-related company. </p>
<p>With the current trading price at $38.32, the median price target of $62.50 suggests a significant profit potential of 61% if the current price aligns with analysts&#8217; expectations.</p>
<h3 class="wp-block-heading">1. Globe Life Inc. </h3>
<p><strong>Globe Life Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GL#NYSE">GL</a>) faced a tumultuous April, plummeting by a staggering 50% due to a critical report by short seller Fuzzy Panda Research. </p>
<p>Despite this, since hitting its lows on April 11, the shares have rebounded by 66%, though remaining still well below pre-report levels. </p>
<p>Despite a slight reduction in Wall Street analysts&#8217; price targets, down from $136 to $130 in the past month, the current stock price of $64.98 presents an enticing short-squeeze opportunity, suggesting a profit potential of 100% if investors can counter and push back against Fuzzy Panda&#8217;s bearish pressure. </p>
<p><em>Chart: Will Globe Life Be Able To Squeeze Short Sellers?</em></p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="495" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/18120911/image-122-1024x495.png" alt="" class="wp-image-298332" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/18120911/image-122-1024x495.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/18120911/image-122-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/18120911/image-122-768x372.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/18120911/image-122-1536x743.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/18120911/image-122.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><figure class="wp-block-table is-style-stripes"><br />
<table>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Price Target vs. Last Price</strong></td>
<td><strong>Last Price</strong></td>
<td><strong>Price Target &#8211; Median</strong></td>
<td><strong>Price Median 1Month Ago)</strong></td>
<td><strong>Price Target (2024 start)</strong></td>
<td><strong>Price Chg. % (MTD)</strong></td>
<td><strong>Price Chg. % (YTD)</strong></td>
</tr>
<tr>
<td>Globe Life Inc.</td>
<td>100.05%</td>
<td>64.98</td>
<td>130.00</td>
<td>136.00</td>
<td>133.56</td>
<td>-44.16%</td>
<td>-46.61%</td>
</tr>
<tr>
<td>Caesars Entertainment, Inc.</td>
<td>61.00%</td>
<td>38.82</td>
<td>62.50</td>
<td>63.00</td>
<td>62.33</td>
<td>-11.25%</td>
<td>-17.19%</td>
</tr>
<tr>
<td>Warner Bros. Discovery, Inc.</td>
<td>57.19%</td>
<td>8.27</td>
<td>13.00</td>
<td>13.20</td>
<td>16.64</td>
<td>-5.27%</td>
<td>-27.33%</td>
</tr>
<tr>
<td>Bio-Rad Laboratories, Inc.</td>
<td>55.51%</td>
<td>280.81</td>
<td>436.70</td>
<td>436.70</td>
<td>436.67</td>
<td>-18.81%</td>
<td>-13.03%</td>
</tr>
<tr>
<td>Carnival Corporation &amp; plc</td>
<td>52.20%</td>
<td>14.46</td>
<td>22.00</td>
<td>22.00</td>
<td>20.78</td>
<td>-11.54%</td>
<td>-22.03%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p>Read now: <em><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38303079/most-s-p-500-stocks-no-longer-trade-above-50-day-average-healthy-pullback-or-is-the">Most S&amp;P 500 Stocks No Longer Trade Above 50-Day Average: Healthy Pullback Or Is The Bull Market Over? </a></em></p>
<p><em>Image generated using artificial intelligence via Midjourney.</em></p>


Large Cap

Mid Cap

Short Sellers

Broad U.S. Equity ETFs

Travel

Tech

ETFs

XLRE

96% Of S&P 500 Stocks Show Upside Potential Vs. Street Estimates: Which Offers The Best Opportunity?

<p>In the latest quarter, 4 analysts provided ratings for Stanley Black &amp; Decker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $90.5, along with a high estimate of $107.00 and a low estimate of $80.00. Highlighting a 4.99% decrease, the current average has fallen from the previous average price target of $95.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713459688_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The perception of Stanley Black &amp; Decker by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Michael Rehaut</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$80.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Joe O'Dea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Stanley Black &amp; Decker. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Stanley Black &amp; Decker compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Stanley Black &amp; Decker's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Stanley Black &amp; Decker's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SWK/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Stanley Black &amp; Decker analyst ratings.</strong></a></p>
<h2>About Stanley Black &amp; Decker</h2>
<p>Stanley Black &amp; Decker Inc is a manufacturer of hand and power tools. The company operates in two reportable segments namely Tools and Outdoor and Industrial. It generates maximum revenue from the Tools and Outdoor segment. The Tools and Outdoor segment is comprised of the Power Tools Group (PTG), Hand Tools, Accessories and Storage (HTAS), and Outdoor Power Equipment (Outdoor) businesses. Geographically, the company generates revenue from the United States, Canada, Other Americas, Europe, and Asia. It derives a majority of its revenue from the United States.</p>
<h3>Stanley Black &amp; Decker's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Stanley Black &amp; Decker's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately <strong>-6.28%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> Stanley Black &amp; Decker's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-8.15%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Stanley Black &amp; Decker's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-3.31%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-1.27%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Stanley Black &amp; Decker's debt-to-equity ratio surpasses industry norms, standing at <strong>0.81</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Verdict: Stanley Black & Decker In The Eyes Of 4 Experts

<p>Northcoast Research  analyst Ryan Connors   upgrades Badger Meter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMI#NYSE">BMI</a>) from Sell to Neutral.</p>


Upgrades

Northcoast Research Upgrades Badger Meter to Neutral

<p>In the last three months, 4 analysts have published ratings on Regency Centers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REG#NASDAQ">REG</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $68.25, along with a high estimate of $72.00 and a low estimate of $60.00. This current average represents a 5.21% decrease from the previous average price target of $72.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713459665_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of Regency Centers among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haendel St. Juste</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Linda Tsai</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$72.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Dori Kesten</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$71.00</td>
<td>$69.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Regency Centers. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Regency Centers compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Regency Centers's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into Regency Centers's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/REG/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Regency Centers analyst ratings.</strong></a></p>
<h2>About Regency Centers</h2>
<p>Regency Centers is the largest shopping center-focused retail REIT. The company's portfolio includes an interest in 482 properties, which includes nearly 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.</p>
<h3>Breaking Down Regency Centers's Financial Performance</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Regency Centers displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately <strong>14.34%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Regency Centers's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>24.02%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Regency Centers's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>1.27%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.7%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Regency Centers's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.65</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Evaluating Regency Centers: Insights From 4 Financial Analysts

<p>In the preceding three months, 5 analysts have released ratings for Carter's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $73.4, a high estimate of $80.00, and a low estimate of $64.00. This current average has increased by 8.26% from the previous average price target of $67.80. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713459643_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Carter's. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$64.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$79.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Warren Cheng</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Sell</td>
<td>$66.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Carter's. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Carter's compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Carter's's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Carter's's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CRI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Carter's analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Carter's</h2>
<p>Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of Carter's sales are in the U.S. and through Carter's brand. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.</p>
<h3>Financial Milestones: Carter's's Journey</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Challenges:</strong> Carter's's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately <strong>-5.95%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Carter's's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>12.18%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Carter's's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>12.82%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Carter's's ROA excels beyond industry benchmarks, reaching <strong>4.45%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Carter's's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>1.28</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Outlook: Carter's Through The Eyes Of 5 Analysts

<p>Honeywell Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) has outperformed the market over the past 20 years by 1.37% on an annualized basis producing an average annual return of 9.05%. Currently, Honeywell Intl has a market capitalization of $124.24 billion. </p>
<p><strong>Buying $1000 In HON:</strong> If an investor had bought $1000 of HON stock 20 years ago, it would be worth <strong>$5,765.51</strong> today based on a price of $190.79 for HON at the time of writing.</p>
<h3>Honeywell Intl's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713459641_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In This Stock 20 Years Ago Would Be Worth $5,800 Today

<p>Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) has outperformed the market over the past 20 years by 6.03% on an annualized basis producing an average annual return of 13.71%. Currently, Accenture has a market capitalization of $199.22 billion. </p>
<p><strong>Buying $1000 In ACN:</strong> If an investor had bought $1000 of ACN stock 20 years ago, it would be worth <strong>$12,991.18</strong> today based on a price of $316.86 for ACN at the time of writing.</p>
<h3>Accenture's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713459635_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


If You Invested $1000 In This Stock 20 Years Ago, You Would Have $13,000 Today

<p><strong>Medtronic's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) short percent of float has risen 8.05% since its last report. The company recently reported that it has <strong>12.43 million shares sold short</strong>, which is 0.94% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.18 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Medtronic Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713459627_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Medtronic has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Medtronic's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Medtronic's peer group average for short interest as a percentage of float is 4.21%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Ideas

Looking Into Medtronic's Recent Short Interest

<p><strong>SM Energy's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SM#NYSE">SM</a>) short percent of float has risen 11.59% since its last report. The company recently reported that it has <strong>10.47 million shares sold short</strong>, which is 13.29% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 7.29 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>SM Energy Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713459621_0_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for SM Energy has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing SM Energy's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, SM Energy's peer group average for short interest as a percentage of float is 6.58%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Peering Into SM Energy's Recent Short Interest

VGSH

CNBC Halftime Report Final Trades: Samsara, Delta Air Lines, Vanguard Short-Term Treasury ETF

<p>In the last three months, 4 analysts have published ratings on 10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for 10x Genomics, revealing an average target of $54.5, a high estimate of $63.00, and a low estimate of $45.00. This current average represents a 4.39% decrease from the previous average price target of $57.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713459621_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The analysis of recent analyst actions sheds light on the perception of 10x Genomics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Justin Bowers</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$55.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$63.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to 10x Genomics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of 10x Genomics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for 10x Genomics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into 10x Genomics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TXG/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on 10x Genomics analyst ratings.</strong></a></p>
<h2>About 10x Genomics</h2>
<p>10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.</p>
<h3>Unraveling the Financial Story of 10x Genomics</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> 10x Genomics's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately <strong>17.76%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> 10x Genomics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-26.61%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> 10x Genomics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-6.59%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> 10x Genomics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-5.12%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> 10x Genomics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.13</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Landscape: 4 Takes On 10x Genomics

<p><strong>DocuSign's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NYSE">DOCU</a>) short percent of float has risen 18.07% since its last report. The company recently reported that it has <strong>8.38 million shares sold short</strong>, which is 4.9% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 4.18 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>DocuSign Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713459616_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for DocuSign has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing DocuSign's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, DocuSign's peer group average for short interest as a percentage of float is 6.69%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


DOCU

(DOCU) - Analyzing DocuSign's Short Interest

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

Chemomab Therapeutics shares are trading higher after the company announced the publication of a new study reinforcing the clinical association of its CCL24 target with disease severity and mortality in patients with systemic sclerosis.

<p>Illinois&#8217; adult-use <a href="https://www.benzinga.com/markets/cannabis/24/03/37824614/heres-where-to-buy-legal-weed-new-stores-launching-cannabis-sales-ahead-of-420-part-1" target="_blank" rel="noreferrer noopener">cannabis sales for March</a> <strong>soared to $148.9 million, marking a 9.81%</strong> <strong>increase from February's $135.6 million</strong>, according to the latest figures released by the Illinois Department of Financial and Professional Regulation (IDFPR). <strong>The combined total of adult-use and medical cannabis sales reached $174.8 million.</strong></p>
<h3 class="wp-block-heading"><strong>Adult-Use Cannabis Hits Second-Highest Sales</strong></h3>
<p>This growth stands as <strong>the second-highest monthly total since the state legalized cannabis in 2020 </strong>and is part of a <a href="https://www.benzinga.com/markets/cannabis/23/09/34981823/exclusive-illinois-is-paving-the-way-for-cannabis-pritzker-says-here-in-the-land-of-lincoln-were" target="_blank" rel="noreferrer noopener">consistent upward trend</a>, with the number of items sold rising by 11.33% to more than 4 million in March from 3.6 million in February. While the IDFPR <a href="https://idfpr.illinois.gov/news/2024/adult-use-cannabis-sales-figures-released-for-march-2024.html">data</a> signals robust demand from both in-state and out-of-state residents, a closer analysis reveals a decreasing trend in purchases by out-of-state residents.</p>
<p>The upward trend is not merely a monthly spike but signifies broader growth within the Illinois cannabis market. <strong>Year-over-year, adult-use cannabis sales surged by 10.45% from March 2023's $134.8 million</strong>, indicating a maturing market and potentially expanding consumer base.</p>
<p><figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="720" height="349" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/18130146/image_720.png" alt="" class="wp-image-298457" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/18130146/image_720.png 720w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/18130146/image_720-300x145.png 300w" sizes="(max-width: 720px) 100vw, 720px" /></figure></p>
<h3 class="wp-block-heading"><strong>A Strong Month For Medical Cannabis</strong></h3>
<p>Parallelly, the medical cannabis sector painted a vibrant picture of patient support and market stability. According to the Medical Cannabis Patient Program (MCPP) <a href="https://mcpp.illinois.gov/updates/mcpp-update-display.mcpp-update---march-31-2024.html" target="_blank" rel="noreferrer noopener">update</a>, <strong>retail sales of medical cannabis for March reached $25.9 million</strong>. This includes $12.2 million in dry flower sales and $13.7 million in concentrates and infused products, reflecting a diverse product interest among the 62,518 unique patients served.</p>
<p>Retail and wholesale figures underscore a flourishing medical cannabis industry. With 55 licensed <a href="https://www.benzinga.com/topic/medical-cannabis" target="_blank" rel="noreferrer noopener">medical cannabis</a> dispensaries operational as of March 2024, the total retail sales for the year tallied to $74.7 million. Since the inception of licensed sales in 2015, the cumulative total retail sales have reached the $2 billion mark, showcasing the sector&#8217;s long-term growth and viability.</p>
<h3 class="wp-block-heading"><strong>A Smashing Future Ahead?</strong></h3>
<p>As <strong>March's record was only surpassed by December 2023&#8217;s sales</strong>, which peaked at $153 million, <strong>Governor JB Pritzker&#8217;s</strong> administration <a href="https://www.benzinga.com/markets/cannabis/24/01/36600938/pritzker-administration-celebrates-as-cannabis-sales-in-illinois-soar-to-new-heights-exceeding-1" target="_blank" rel="noreferrer noopener">continues to demonstrate its full support</a>, solidifying Illinois&#8217; status as an emerging powerhouse in the U.S. cannabis industry.</p>
<p><strong><em>Read also: </em></strong><a href="https://www.benzinga.com/markets/cannabis/24/04/38281040/top-cannabis-diversification-secrets-industry-leaders-reveal-strategies-for-success-at-benzinga-" target="_blank" rel="noreferrer noopener"><em>Top Cannabis Diversification Secrets: Industry Leaders Reveal Strategies For Success At Benzinga Conference</em></a></p>


Cannabis

Government

Illinois Cannabis Sales Hit Near-Record In March With $174.8M, Up Nearly 10% From Feb

<p>Cybersecurity company <strong>Zscaler Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) is considered a &#8220;<a href="https://www.benzinga.com/news/24/04/38252496/the-zacks-analyst-blog-highlights-microsoft-nvidia-twilio-meta-platforms-and-zscaler">Top Pick on the Zacks Analyst Blog</a>.&#8221; </p>
<p>It&#8217;s also a leader in the SASE (Secure Access Service Edge) market, which is still in its "early innings," according to KeyBanc Capital Markets analyst Eric Heath.</p>
<p><strong>The Zscaler Analyst: </strong>Heath upgraded the rating for Zscaler to Overweight, while establishing a price target of $220.</p>
<p><strong>The Zscaler Thesis: </strong>The new price target reflects a "modest premium" to the over 20% growth group, Heath said in the upgrade note.</p>
<p><em>Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.</em></p>
<p>The analyst mentioned four reasons for the upgrade:</p>
<ul>
<li>While the landscape remains competitive, concerns are easing.</li>
<li>The are catalysts to SASE adoption in the near term. "The Ivanti VPN vulnerability exploits, SASE tied #4 priority in our 1Q24 VAR survey (vs. #10 last quarter), and ongoing weakness in firewall suggests network security budgets may orient toward SASE."</li>
<li>The channel and survey feedback during the first quarter has been positive.</li>
<li>The stock is currently trading in-line with the over 20% growth group versus its historical two-year premium.</li>
</ul>
<p><strong>ZS Price Action: </strong>Shares of Zscaler had risen by 2.23% to $176.81 at the time of publication on Thursday.</p>
<p><em>Image: Shutterstock</em></p>


Analyst Color

4 Reasons Why This Zscaler Analyst Is Turning Bullish: 'Q1 Feedback Is Positive'

Income In The New Macro Regime

Fixed Income Investment Outlook Q3 2023: Last Mile For Tightening

Overlay Shares Short Term Bond ETF declares quarterly distribution of $0.2851

Moving From Cash To Short-Term Bonds

Is It Time To Move Off The Sidelines?

Short-Term Bonds: A Compelling Option In The Face Of Fed Cuts

Overlay Shares Short Term Bond ETF declares quarterly distribution of $0.3520

ACTV

AEMB

AFMC

AFSM

ANGL

ARKK

AVSF

AVUV

AYTEF

BAPR

BBCB

BBHY

BBSA

BGRN

BILS

BKHY

BKSB

BNDX

BSJN

BSJO

BSJP

BSJQ

BSJR

BSJS

BSJT

CBON

CEMB

CORP

DFHY

DFSD

DRSK

EBND

EFIX

EMBD

EMCB

EMHC

EMHY

EMLC

EMTL

ESCR

ESEB

ESHY

FAIL

FALN

FCOR

FCSH

FDHY

FEMB

FIBR

FLCO

FLHY

FLIA

FLTB

FMHI

FTSD

GBIL

GHYB

GHYG

GIGB

GOVT

GOVZ

GSIG

HEEM

HSRT

HYBB

HYDB

HYDW

HYEM

HYGH

HYGV

HYLB

HYLD

HYLS

HYMB

HYMU

HYUP

HYXF

HYXU

IBHC

IBHD

IBHE

IBHF

IBHG

IBND

IGBH

IGEB

IGIB

IGOV

IGSB

IHYF

IIGD

ISHG

ISTB

IVOO

IVOV

JHCB

JPMB

KBND

KHYB

KORP

LDSF

LDUR

LEMB

LGOV

LKOR

LMBS

LQDB

LQDH

LQDI

LSST

MBBB

MINC

NUHY

NUSA

OPER

PFIG

PGHY

PHYL

PICB